Johnson & Johnson

-

Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Johnson & Johnson
TickerJNJ
CIK #0000200406
CUSIP478160104
SectorLife Sciences
IndustryPharmaceutical Preparations
Phone7325242455
AddressOne Johnson & Johnson Plz
New Brunswick, NJ 08933
Source [EDGAR]
Market Cap, 13F ($BB)
4003202401608002011201320152018
Business

Johnson & Johnson and its subsidiaries (the Company) have approximately 132,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company's primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.

The Executive Committee of Johnson & Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Company's three business segments: Consumer, Pharmaceutical and Medical Devices. Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located.

The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. Additional information required by this item is incorporated herein by reference to the narrative and tabular descriptions of segments and operating results under: "Item 7. Management's Discussion and Analysis of Results of Operations and Financial Condition" of this Report; and Note 18 "Segments of Business and Geographic Areas" of the Notes to Consolidated Financial Statements included in Item 8 of this Report.

CIK Filing 2011 - 2021
[0000200406] 10-K
[0000200406] 10-Q
[0000200406] 13F-NT
[0000200406] 3
[0000200406] 4
[0000200406] 5
[0000200406] 8-K
[0000200406] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
State Street Corp Johnson & Johnson [2021-02-12] 5.47
Johnson & Johnson Fusion Pharmaceuticals Inc [2020-07-06] 0.0
State Street Corp Johnson & Johnson [2020-02-13] 5.77
Johnson & Johnson BiomX Inc [2019-11-26] 0.3
Johnson & Johnson MeiraGTx Holdings PLC [2019-03-04] 8.7
State Street Corp Johnson & Johnson [2019-02-13] 5.7
Johnson & Johnson PhaseBio Pharmaceuticals Inc [2019-01-22] 6.6
Johnson & Johnson Provention Bio Inc [2019-01-22] 6.4
State Street Corp Johnson & Johnson [2018-02-14] 5.81
State Street Corp Johnson & Johnson [2017-02-07] 5.65
Johnson & Johnson Merus NV [2017-01-18] 7.4
Johnson & Johnson Tracon Pharmaceuticals Inc [2016-10-31] 6.4
Johnson & Johnson Protagonist Therapeutics Inc [2016-08-19] 15.0
State Street Corp Johnson & Johnson [2016-02-16] 5.4
Johnson & Johnson Aduro Biotech Inc [2016-02-12] 6.2
Johnson & Johnson Catalyst Biosciences Inc [2015-08-28] 0.0
Johnson & Johnson Achillion Pharmaceuticals Inc [2015-07-07] 15.6
State Street Corp Johnson & Johnson [2015-02-12] 5.7
Vanguard Group Inc Johnson & Johnson [2015-02-10] 5.85
Johnson & Johnson Aquinox Pharmaceuticals Inc [2015-02-06] 15.1
Johnson & Johnson GI Dynamics Inc [2015-02-06] 6.0
Johnson & Johnson Macrogenics Inc [2015-02-05] 6.5
Johnson & Johnson Aldeyra Therapeutics Inc [2015-02-05] 31.4
Johnson & Johnson Nevro Corp [2015-02-05] 12.4
Johnson & Johnson Genocea Biosciences Inc [2015-02-05] 8.0
Johnson & Johnson Minerva Neurosciences Inc [2014-07-17] 18.0
State Street Corp Johnson & Johnson [2014-02-03] 5.7
Johnson & Johnson Prothena Corp PLC [2013-02-13] 14.82
State Street Corp Johnson & Johnson [2013-02-11] 5.5
State Street Corp Johnson & Johnson [2012-02-09] 5.1
Form 3/4/5 Filer 2011-2021
Johnson & Johnson
Johnson & Johnson Innovation - JJDC, Inc.
CVRX Inc
Hewson Marillyn A
Washington A. Eugene
Weinberger Mark A
Fasolo Peter
Sneed Michael E
Duato Joaquin
Taubert Jennifer L
Wengel Kathryn E
Wolk Joseph J
Decker Robert J
Gorsky Alex
Mongon Thibaut
Stoffels Paulus
McEvoy Ashley
Ullmann Michael H
West Nadja
Prince Charles
Mulcahy Anne M
McClellan Mark B.
Joly Hubert
Doudna Jennifer A
Davis Ian
Davis D Scott
Beckerle Mary C
Williams Ronald A
Fusion Pharmaceuticals Inc.
Perez William D
Mesquita Jorge S.
Kapusta Ronald A
Provention Bio, Inc.
Inspire Medical Systems, Inc.
Peterson Sandra E
Caruso Dominic J
Achillion Pharmaceuticals Inc
Minerva Neurosciences, Inc.
Pruden Gary J
Lindquist Susan L
Protagonist Therapeutics Inc
Nevro Corp
Coleman Mary Sue
Aquinox Pharmaceuticals USA Inc
Cullen James
Mullin Leo F
Cosgrove Stephen J
Aldeyra Therapeutics, Inc.
Johns Michael M E
Genocea Biosciences Inc
Satcher David
Weldon William C
Deyo Russell C
McCoy Sherilyn S
Universal Biosensors Inc
MM Shares Owned of 2,682.0 MM Total
Firm Period DFND Voting Shares
Vanguard Group Inc [2021-03-31] SOLE 0.0 218.5
BlackRock Inc. [2021-03-31] SOLE 163.1 189.7
State Street Corp [2021-03-31] DFND 90.1 140.3
Geode Capital Management LLC [2021-03-31] DFND 40.7 40.8
Bank of America Corp /DE/ [2021-03-31] DFND 8.6 33.9
Wellington Management Group LLP [2021-03-31] DFND 0.0 33.9
State Farm Mutual Automobile Insurance Co [2021-03-31] SOLE 31.7 31.7
Northern Trust Corp [2021-03-31] DFND 10.1 30.1
Bank of New York Mellon Corp [2021-03-31] DFND 22.6 29.6
Morgan Stanley [2021-03-31] DFND 2.8 24.3
JPMorgan Chase & Co [2021-03-31] DFND 20.4 22.5
Wells Fargo & Company/MN [2021-03-31] DFND 5.3 22.4
Massachusetts Financial Services Co /MA/ [2021-03-31] SOLE 21.5 22.2
Ameriprise Financial Inc [2021-03-31] DFND 0.0 18.3
Capital Research & Management Co - Division 3 [2021-03-31] DFND 18.3 18.3
Legal & General Group Plc [2021-03-31] DFND 12.4 16.6
Schwab Charles Investment Management Inc [2021-03-31] SOLE 15.5 15.9
Royal Bank of Canada [2021-03-31] DFND 14.5 15.6
Price T Rowe Associates Inc /MD/ [2021-03-31] SOLE 7.2 15.4
Deutsche Bank AG [2021-03-31] DFND 9.0 15.3
Nuveen Asset Management LLC [2021-03-31] DFND 14.3 14.4
Franklin Resources Inc [2021-03-31] DFND 13.9 13.9
UBS Group AG [2021-03-31] DFND 0.0 13.5
Goldman Sachs Group Inc [2021-03-31] DFND 10.6 13.3
FMR LLC [2021-03-31] DFND 0.5 13.0
Robert Wood Johnson Foundation [2021-03-31] SOLE 12.8 12.8
Capital World Investors [2021-03-31] DFND 11.9 11.9
California Public Employees Retirement System [2021-03-31] SOLE 11.4 11.4
Vanguard Group Inc [2021-03-31] DFND 0.0 11.2
Swiss National Bank [2021-03-31] SOLE 11.0 11.0
Prev | Page 1 | Next
Terms | Privacy | Guide
tony@aum13f.com